NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyメs international Phase 2…
On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10…
On Mar. 2, 2021, the Biden Administration has helped forge a historic manufacturing collaboration between two of the…
On Feb. 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization…
On Feb. 28, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Preventionメs (CDC)…
On Feb. 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued…
On Feb. 26, 2021, Roche announced it had been granted special approval by the German Federal Institute for…
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
On Feb. 26, 2021, Johnson & Johnson announced that the FDA Vaccines and Related Biological Products Advisory Committee…
On Feb. 26, 2021, Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization…
On Feb. 26, 2021, Regeneron announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
On Feb. 25, 2021, the U.S. Food and Drug Administration announced that it was allowing undiluted frozen vials…
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
On Feb. 25, 2021, Chimerix reported topline results from the first cohort of its randomized, double-blind, placebo-controlled Phase…
On Feb. 25, 2021, Pfizer and BioNTech announced they had begun an evaluation of the safety and immunogenicity…
On Feb. 25, 2021, Regeneron announced changes to the phase 3 trial assessing investigational REGEN-COVル (casirivimab with imdevimab)…
On Feb. 25, 2021, scientists at the Childrenメs Medical Center Research Institute at UT Southwestern announced they had…
On Feb. 24, 2021, scientists at the University of Oxford reported that overall deaths did not increase in…
On Feb. 24, 2021, Ghana became the first country outside India to receive COVID-19 vaccine doses shipped via…
On Feb. 24, 2021, XPhyto announced that it has placed the first order for its rapid point-of-care SARS-CoV-2…
On Feb. 24, 2021, Quest Diagnostics introduced a new COVID-19 testing service that aids in providing insight into…
On Feb. 23, 2021, the NIH announced that a randomized, placebo-controlled Phase 1 clinical trial of two monoclonal…
On Feb. 23, 2021, Cue Health announced that its molecular point-of-care COVID-19 Test had received the CE mark,…
On Feb. 23, 2021, Nabriva Therapeutics announced publication of a study documenting the high rates of macrolide-resistant Streptococcus…
On Feb. 23, 2021, PerkinElmer announced the launch of the PerkinElmerᆴ COVID-19 Antigen Test for the qualitative detection…
On Feb. 22, 2021, Amyris announced highly promising preliminary data in a pre-clinical study of its ribonucleic acid…
On Feb. 22, 2021, Biohaven Pharmaceutical announced that a hyperimmune globulin mimic (HGM) developed with Biohaven’s proprietary MATE…
On Feb. 22, 2021, BD (Becton, Dickinson) and Scanwell Health, a leader in smartphone-enabled at-home medical tests, announced…
On Feb. 19, 2021, the ACT Accelerator partnership welcomed over US$ 4.3 billion of new investments from the…